This inventor holds 2 USPTO granted patents, plus 1 CIPO patent and 2 EPO patents. Top assignee: Eisai R&d Management Co., Ltd.. Active years: 2018.
Company Filing History:
Years Active: 2018
Title: The Innovations of Andrew Payne
Introduction
Andrew Payne is a notable inventor based in Hertfordshire, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that may aid in treating cognitive deficits associated with neurological disorders.
Latest Patents
Andrew Payne holds 2 patents, with his latest innovations focusing on 4-azaindole derivatives. These derivatives act as modulators of the muscarinic acetylcholine receptor (mAChR) M1. They may be effective in the prevention, disease modification, or symptomatic treatment of cognitive deficits related to conditions such as Alzheimer-type dementia (AD) and dementia with Lewy bodies (DLB). His work also includes a pharmaceutical composition that comprises a 4-azaindole derivative as an active ingredient.
Career Highlights
Andrew is currently employed at Eisai R&D Management Co., Ltd., where he continues to push the boundaries of pharmaceutical research. His work is crucial in the ongoing fight against neurological disorders, and his patents reflect his commitment to innovation in this vital area of healthcare.
Collaborations
Throughout his career, Andrew has collaborated with talented individuals such as Afzal Khan and James Edward Kitulagoda. These partnerships have likely contributed to the success of his research and the development of his patents.
Conclusion
Andrew Payne's contributions to the field of pharmaceuticals through his innovative patents demonstrate his dedication to improving treatments for cognitive deficits. His work is essential in advancing our understanding and management of neurological disorders.